OUR SCIENCE
Our lead asset, TNAT-101, is an orally bioavailable, small molecule inhibitor of the novel target BCL3. BCL3 is a transcriptional regulator of multiple pathways critical for cancer initiation, maintenance and progression. It plays an important role in tumor growth, cell death, migration, metastasis and cancer stem cell viability.
TARGETING CANCER AT ITS ROOT
TNA is committed to developing novel targeted therapies to treat cancers with a high unmet need. By targeting Cancer Stem Cells, we believe these therapies will provide long-term survival benefits to patients without detrimental side effects.
THE DEVELOPMENT OF NOVEL THERAPEUTICS
TNAT-101 was optimised using state of the art technology to molecularly model BCL3 interaction with its cognate partners p50 and p52. TNAT-101 disrupts this interaction and prevents downstream signalling.
EFFICACY
TNAT-101 has demonstrated significant preclinical efficacy in a range CRC and TNBC models both in vitro and in vivo. TNAT-101 treatment leads to regressions in KRAS mutant models of CRC and up to 95% anti-metastatic efficacy – leading to significant improvements in survival.
INDICATIONS
TNAT-101 primary indications include CRC and TNBC, however, significant efficacy has also been observed as single agent or in combination with standard of care agents across a wider range of indications. BCL3 has been implicated as a key regulator of disease progression or poor prognosis in over 10 different indications, evidencing the potential broader application
of TNAT-101 within cancer treatment.
SAFETY
TNAT-101 has completed a significant preclinical safety package to date including both in vitro and in vivo assessments. Single and short-term repeat dose toxicology studies have shown that TNAT-101 is well tolerated up to 100 x the biologically effective dose observed in animals.
RESOURCES
We offer authoritative information on a wide range of cancer topics
Visit our News page for recent articles and to find the latest research, treatment, prevention, and screening information for a particular type of cancer as well as information on a wide range of cancer topics.
The discovery of a novel
anti-metastatic BCL3 inhibitor
The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths...
Bcl3 selectively promotes metastasis of ErbB2-driven breast cancer
Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tumors. Studies in cell lines suggest that its oncogenic effects are mediated through the induction of...
The Proto-oncogene BCL3 induces immune checkpoint PD-L1 expression
The proto-oncogene Bcl3 induces survival and proliferation in cancer cells; however, its function and regulation in ovarian cancer (OC) remain unknown...